{"id":"W4213230310","doi":"10.1200/jco.20.02363","title":"Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Medicine; Pembrolizumab; Renal cell carcinoma; Oncology; Internal medicine; Open label; Phases of clinical research; First line therapy; Chemotherapy; Immunotherapy; Cancer; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001164078,0.0003346203,0.00251244,0.0002120349,0.00007565332,0.00001753351,0.0004279404,0.0003049503,0.0003070529],"category_scores_gemma":[0.0003427705,0.0002275607,0.0002518201,0.0003924705,0.0001403341,0.0002020927,0.0001792119,0.001031635,0.000006926431],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003780757,"about_ca_system_score_gemma":0.001827076,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005825141,"about_ca_topic_score_gemma":0.0001071487,"domain_scores_codex":[0.9944775,0.0007777052,0.003116995,0.0004950252,0.0007564197,0.0003763313],"domain_scores_gemma":[0.9943461,0.0009849598,0.002532817,0.0005601025,0.001127645,0.0004483898],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"nonrandomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2561837,0.4328931,0.163084,0.00005291723,0.0005025088,0.005244248,0.001236359,0.0001880487,0.003990695,0.000003038954,0.0003258,0.1362956],"study_design_scores_gemma":[0.277911,0.5611708,0.1481002,0.00008458559,0.0002526496,0.00007170391,0.0003489255,0.00002323956,0.008316784,0.00002792065,0.003534016,0.0001581702],"study_design_candidate":"nonrandomized_trial","study_design_consensus":"nonrandomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9940129,0.0009870532,0.0000104953,0.0009671714,0.0003565568,0.001208472,0.000005506544,0.000006267256,0.002445599],"genre_scores_gemma":[0.9954516,0.000590181,0.002278267,0.0009675628,0.0002247569,0.00001553663,0.0000112254,0.0000594135,0.0004014766],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1361375,"threshold_uncertainty_score":0.9279656,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1270295961272147,"score_gpt":0.4285247223605393,"score_spread":0.3014951262333247,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}